{"id":4401,"date":"2024-10-20T22:49:15","date_gmt":"2024-10-21T03:49:15","guid":{"rendered":"https:\/\/www.bocsci.com\/blog\/?p=4401"},"modified":"2024-10-21T02:54:03","modified_gmt":"2024-10-21T07:54:03","slug":"fda-approved-weight-loss-medications","status":"publish","type":"post","link":"https:\/\/www.bocsci.com\/blog\/fda-approved-weight-loss-medications\/","title":{"rendered":"FDA\u00a0Approved Weight Loss Medications"},"content":{"rendered":"\n

History of drugs for weight loss<\/strong><\/strong><\/h2>\n\n\n\n

In 1760, English physician Malcolm Flemyng was the first to refer to obesity as a disease. The public’s view of obesity could shift if it were viewed as a medical condition rather than a social parameter. People are considered overweight if their body mass index (BMI) is 25 or higher, and obese if it’s 30 or higher. The World Health Organization (WHO) estimates that over 1 billion people around the world are obese, putting them at a higher risk of various health complications. Diabetes mellitus, cardiovascular disease, hypertension, stroke, decreased female fertility, mental health issues, worse COVID-19 outcomes, and an increased risk of cardiovascular disease are all linked to obesity. In the United States, anti-obesity drugs have a long and storied past. Until the US Food and Drug Administration (FDA) banned amphetamines as a weight-loss aid in 1979 due to their addictive potential, they were extensively promoted for their ability to suppress hunger during the post-war era. After that, fen-phen, a diet pill that combined the anorectics phentermine and fenfluramine, had a meteoric rise to fame in the mid-1990s. However, the FDA eventually took the product from shelves on concerns about major heart valve issues. Meridia, Acomplia, and Ephedra were all removed off pharmacy shelves due to inconsistent safety records, indicating that more recent attempts have not fared any better.<\/p>\n\n\n\n

Efficacy of <\/strong>c<\/strong>urrently <\/strong>a<\/strong>pproved medications for <\/strong>o<\/strong>besity<\/strong><\/strong><\/h2>\n\n\n\n

Currently, five drugs have been authorized by the FDA for the treatment of obesity. Lorcaserin was the sixth medicine to be licensed for weight reduction, but it was removed after eight years of clinical usage because of concerns about an increased risk of cancer.<\/p>\n\n\n

\n
\"Approved<\/a>
A comparison of approved weight loss therapies in obesity. (Williams D M., et al<\/em>., 2020)<\/figcaption><\/figure><\/div>\n\n\n

Orlistat<\/strong><\/strong><\/a>: <\/strong>Orlistat, an inhibitor of pancreatic and stomach lipases, can reduce fat absorption by 30% and aid in weight loss. Results showing a decrease in BMI, weight, waist circumference, total cholesterol, and low-density lipoprotein (LDL) cholesterol were obtained by Yu et al.<\/em> when orlistat was administered in conjunction with a healthy diet or diet plus exercise rather than diet alone. Researchers Khera et al.<\/em> discovered that compared to those given a placebo, those given orlistat were more likely to lose 5% of their starting weight (Odds ratio (OR) 2.70, 95% credible interval (CrI) 2.34-3.09, surface under the cumulative ranking curve (SUCRA) 0.22). Orlistat resulted with 2.6 kg more weight reduction at one year compared to placebo (95% CrI -3.04 to -2.16 kg). Over the course of seven months, the XENSOR trial conducted by Gorgojo-Martinez et al. shown that both orlistat and liraglutide considerably reduced weight, fasting glucose level, systolic blood pressure, LDL cholesterol<\/a>, and alanine transaminase. The weight loss was 3.3 kg with orlistat and 7.7 kg with liraglutide, respectively. Compared to 64.7% of liraglutide individuals, 27.4% of orlistat participants dropped 5% or more of their baseline weight. According to Grabarczyk’s research, patients who took orlistat for 20 weeks saw a 2.1% weight loss compared to baseline, those who took phentermine-topiramate for 4.1%, and those who took phentermine for 3.6%. In comparison, patients who participated in MOVE!, the weight management program offered by the Veterans Administration (VA), which required at least three clinic visits, saw a slimmer patient.<\/p>\n\n\n\n

Orlistat<\/strong> molecules at BOC Sciences<\/strong><\/strong><\/p>\n\n\n\n

Name<\/td>CAS<\/td>Category<\/td><\/tr>
Orlistat<\/a><\/td>96829-58-2<\/td>Impurities<\/td><\/tr>
Orlistat Impurity<\/a><\/td> <\/td>Impurities<\/td><\/tr>
Orlistat Impurity 3<\/a><\/td> <\/td>Impurities<\/td><\/tr>
Orlistat degradation product sodium salt<\/a><\/td> <\/td>Impurities<\/td><\/tr>
N-Nitroso Orlistat<\/a><\/td> <\/td>Impurities<\/td><\/tr>
(R,S,S,S)-Orlistat<\/a><\/td>104872-28-8<\/td>Impurities<\/td><\/tr>
Orlistat USP Related Compound E<\/a><\/td>1072902-75-0<\/td>Impurities<\/td><\/tr>
N-Deformyl-N-benzyloxycarbonyl Orlistat<\/a><\/td>108051-94-1<\/td>Impurities<\/td><\/tr>
(S,R,R,R)-Orlistat<\/a><\/td>111466-61-6<\/td>Impurities<\/td><\/tr>
(S,S,R,R)-Orlistat<\/a><\/td>111466-62-7<\/td>Impurities<\/td><\/tr>
(S,R,S,S) Orlistat<\/a><\/td>111466-63-8<\/td>Impurities<\/td><\/tr>
Octyl Orlistat<\/a><\/td>1243011-56-4<\/td>Impurities<\/td><\/tr>
L-Valine Orlistat<\/a><\/td>1243107-50-7<\/td>Main Product<\/td><\/tr>
Orlistat Impurity 2<\/a><\/td>130676-63-0<\/td>Impurities<\/td><\/tr>
Orlistat Related Compound [(S)-3-Hexyl-5,6-dihydro-6-undecyl-2H-pyran-2-one]<\/a><\/td>130676-64-1<\/td>Impurities<\/td><\/tr>
Orlistat Impurity M1<\/a><\/td>130676-66-3<\/td>Impurities<\/td><\/tr>
Orlistat Related Compound D<\/a><\/td>130793-27-0<\/td>Impurities<\/td><\/tr>
Orlistat Related Compound ((2S,3R,5S)-5-[(N-Formyl-L-leucyl)oxy]-2-hexyl-3-hydroxyhexadecanoic acid)<\/a><\/td>130793-28-1<\/td>Impurities<\/td><\/tr>
N-Deformyl-N-pivaloyl Orlistat<\/a><\/td>1356017-35-0<\/td>Impurities<\/td><\/tr>
5-Methyl-L-Norleucine Orlistat Analogue<\/a><\/td>1356847-30-7<\/td>Impurities<\/td><\/tr>
Orlistat-[d3]<\/a><\/td>1356930-46-5<\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
Orlistat USP Related Compound B (Diisopropyl Hydrazine-1, 2-Dicarboxylate)<\/a><\/td>19740-72-8<\/td>Impurities<\/td><\/tr>
Orlistat USP Related Compound C (Triphenylphosphine Oxide)<\/a><\/td>791-28-6<\/td>Impurities<\/td><\/tr>
Orlistat Dimer Impurity<\/a><\/td>881900-54-5<\/td>Impurities<\/td><\/tr>
N-Formyl-L-leucine (3S,4S,6S)-3-Hexyltetrahydro-2-oxo-6-undecyl-2H-pyran-4-yl Ester<\/a><\/td>130676-65-2<\/td>Main Product<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Phentermine-Topiramate<\/strong>: <\/strong>Phentermine is a sympathomimetic agent that curtails appetite by elevating norepinephrine levels in the central nervous system. Topiramate<\/a>, a gamma-aminobutyric acid (GABA) receptor agonist<\/a>, suppresses hunger and enhances fullness. It is frequently utilized for the management of epilepsy and migraine headaches. The FDA has authorized the combination of phentermine and topiramate for obesity control. Substantial weight reduction linked to phentermine-topiramate vs to placebo. A 5% weight reduction was seen in 75% of persons administered phentermine-topiramate compared to 23% of those getting a placebo (OR 9.22, 95% CrI 6.63-12.85, SUCRA 0.95) and 44% of individuals taking orlistat (OR 2.70, 95% CrI 2.34-3.09, SUCRA 0.22). After one year, the excess weight reduction relative to placebo was 8.8 kg (95% CrI -10.20 to -7.42 kg), whereas with orlistat, it was 2.6 kg compared to placebo (95% CrI -3.04 to -2.16 kg).<\/p>\n\n\n\n

Topiramate molecules at BOC Sciences<\/strong><\/strong><\/p>\n\n\n\n

Name<\/td>CAS<\/td>Category<\/td><\/tr>
Topiramate<\/a><\/td>97240-79-4<\/td>Impurities<\/td><\/tr>
Topiramate D-galactopyranose<\/a><\/td> <\/td>Carbohydrates, Nucleosides & Nucleotides<\/td><\/tr>
Topiramate Dimer Impurity<\/a><\/td> <\/td>Impurities<\/td><\/tr>
Topiramate impurity B<\/a><\/td> <\/td>Carbohydrates, Nucleosides & Nucleotides<\/td><\/tr>
N-Methyl Topiramate-d3<\/a><\/td> <\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
Topiramate Azidosulfate<\/a><\/td>106881-35-0<\/td>Impurities<\/td><\/tr>
Topiramate Desacetal Impurity (4,5-diol-Topiramate)<\/a><\/td>106881-41-8<\/td>Impurities<\/td><\/tr>
Topiramate Didesacetal Impurity<\/a><\/td>106881-42-9<\/td>Impurities<\/td><\/tr>
Topiramate-[13C6]<\/a><\/td>1217455-55-4<\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
Topiramate-[d12]<\/a><\/td>1279037-95-4<\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
R-Hydroxy topiramate<\/a><\/td>198215-60-0<\/td>Carbohydrates, Nucleosides & Nucleotides<\/td><\/tr>
S-Hydroxy topiramate<\/a><\/td>198215-62-2<\/td>Impurities<\/td><\/tr>
Topiramate Related Compound A<\/a><\/td>20880-92-6<\/td>Impurities<\/td><\/tr>
2,3-Desisopropylidene Topiramate<\/a><\/td>851957-35-2<\/td>Impurities<\/td><\/tr>
Topiramate EP Impurity D<\/a><\/td>950603-46-0<\/td>Impurities<\/td><\/tr>
Topiramate N-Methyl Impurity<\/a><\/td>97240-80-7<\/td>Impurities<\/td><\/tr>
1,2:4,5-di-O-Isopropylidene-beta-D-fructopyranose<\/a><\/td>25018-67-1<\/td>Impurities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Naltrexone\/Bupropion: <\/strong>Naltrexone functions as an opiate antagonist, whilst bupropion<\/a> serves as a mild inhibitor of dopamine and noradrenaline reuptake. It has received approval from both the FDA and EMA for the treatment of obesity. These medications together induce satiety by promoting the production of melanocyte-stimulating hormone (MSH) from hypothalamic pro-opiomelanocortin (POMC) cells, resulting in decreased food consumption and higher energy expenditure. Naltrexone\/bupropion, similar to other obesity pharmacotherapies, is advised for those with a BMI of \u226530 kg\/m2<\/sup> or \u226527 kg\/m2<\/sup> when accompanied by additional obesity-related comorbidities. An extra yearly reduction of 4.8% in total body weight (average 4.4 kg) has been seen, accompanied by side symptoms such as nausea, headache, and dizziness.<\/p>\n\n\n\n

Bupropion molecules at BOC Sciences<\/strong><\/strong><\/p>\n\n\n\n

Name<\/td>CAS<\/td>Category<\/td><\/tr>
Bupropion<\/a><\/td>34911-55-2<\/td>Inhibitor<\/td><\/tr>
threo-Hydroxy Bupropion-[d9] Hydrochloride<\/a><\/td> <\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
3-Deschloro-2-Chloro Bupropion HCl<\/a><\/td>1049718-57-1<\/td>Impurities<\/td><\/tr>
Bupropion Related Compound A<\/a><\/td>1049718-72-0<\/td>Impurities<\/td><\/tr>
Bupropion Impurity E<\/a><\/td>10557-17-2<\/td>Impurities<\/td><\/tr>
4-Fluoro bupropion<\/a><\/td>1076198-12-3<\/td>Impurities<\/td><\/tr>
4-Fluorohydroxy bupropion<\/a><\/td>1076198-13-4<\/td>Impurities<\/td><\/tr>
Bupropion-[d9] Hydrochloride<\/a><\/td>1189725-26-5<\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
4-Chloro Bupropion<\/a><\/td>1193779-34-8<\/td>Impurities<\/td><\/tr>
4-Chloro Bupropion Fumarate<\/a><\/td>1193779-36-0<\/td>Impurities<\/td><\/tr>
5-Chloro Bupropion Fumarate<\/a><\/td>1193779-50-8<\/td>Impurities<\/td><\/tr>
Hydroxy Bupropion-[d6]<\/a><\/td>1216893-18-3<\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
rac erythro-Dihydro Bupropion-[d9]<\/a><\/td>1217684-77-9<\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
rac threo-Dihydro Bupropion-[d9] Hydrochloride<\/a><\/td>1392209-60-7<\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
Bupropion Related Compound C<\/a><\/td>152943-33-4<\/td>Impurities<\/td><\/tr>
(S,S)-Hydroxy Bupropion<\/a><\/td>192374-14-4<\/td>Impurities<\/td><\/tr>
(R,R)-Hydroxy Bupropion<\/a><\/td>192374-15-5<\/td>Impurities<\/td><\/tr>
Bupropion HCl<\/a><\/td>31677-93-7<\/td>Impurities<\/td><\/tr>
(S)-Bupropion Hydrochloride<\/a><\/td>324548-45-0<\/td>Impurities<\/td><\/tr>
Bupropion Morpholinol<\/a><\/td>357399-43-0<\/td>Impurities<\/td><\/tr>
erythro-Hydroxy Bupropion HCl<\/a><\/td>357628-62-7<\/td>Impurities<\/td><\/tr>
threo-Hydroxy Bupropion HCl<\/a><\/td>357637-18-4<\/td>Impurities<\/td><\/tr>
2-(TERT-BUTYLAMINO)PROPIOPHENONE HYDROCHLORIDE; DESCHLORO BUPROPION<\/a><\/td>63199-74-6<\/td>Main Product<\/td><\/tr>
Bupropion Related Compound F<\/a><\/td>857233-13-7<\/td>Impurities<\/td><\/tr>
Bupropion hydrobromide<\/a><\/td>905818-69-1<\/td>Main Product<\/td><\/tr>
2-(Tert-butylamino)-1-(2-chlorophenyl)propan-1-one<\/a><\/td>1049974-40-4<\/td>Impurities<\/td><\/tr>
3-Chloro-a-[1-[(1,1-dimethylethyl)amino]ethyl]benzenemethanol<\/a><\/td>119802-68-5<\/td>Main Product<\/td><\/tr>
(3R,5RS,6RS)-6-(3-Chlorophenyl)-6-Hydroxy-5-Methyl-3-Thiomorpholine Carboxylic Acid<\/a><\/td>1246812-57-6<\/td>Impurities<\/td><\/tr>
2-(tert-Butylamino)-3′, 4′-Dichloropropiophonone HCl<\/a><\/td>1346598-72-8<\/td>Impurities<\/td><\/tr>
THREO-DIHYDROBUPROPION<\/a><\/td>153365-82-3<\/td>Main Product<\/td><\/tr>
(R*,S*)-2-(T-BUTYLAMINO)1-(3-CHLOROPHENYL) PROPANOL<\/a><\/td>292055-72-2<\/td>Main Product<\/td><\/tr>
2-(N-tert-Butylamino)propiophenone<\/a><\/td>34509-36-9<\/td>Impurities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Liraglutide<\/strong><\/strong><\/a>:<\/strong> Liraglutide is a glucagon-like peptide-1 (GLP-1) agonist<\/a>, initially developed for the management of type 2 diabetes (T2D). Administered as a daily injection at a dosage of 3.0 mg, in contrast to a maximum of 1.8 mg daily for the treatment of T2D. Liraglutide facilitates weight reduction by augmenting satiety by hypothalamic activation and prolonging gastric emptying, thus reducing food consumption. It is sanctioned by the FDA and EMA to facilitate weight reduction in individuals with a BMI of \u226530 kg\/m2<\/sup> or \u226527 kg\/m2<\/sup> with obesity-related comorbidities. Prevalent adverse effects encompass nausea, vomiting, and pancreatitis. A supplementary yearly weight reduction of 5.3-5.9 kg has been noted in comparison to placebo.<\/p>\n\n\n\n

Semaglutide:<\/strong> Semaglutide is the latest GLP-1 analogue authorized for Type 2 Diabetes (T2D) and is presently administered via subcutaneous injection at a maximum dosage of 1.0 mg once weekly for T2D therapy. It is authorized for use as monotherapy for individuals who cannot tolerate metformin or as an adjunct therapy. The total weight reduction linked to semaglutide administration is up to 4.6 kg and 6.5 kg at dosages of 0.5 mg and 1.0 mg, respectively, during a duration of 40 weeks. Comparative investigations have indicated that semaglutide 1.0 mg had superior weight reduction effectiveness compared to dulaglutide 1.5 mg (6.5 kg versus 3.0 kg). A phase II dose-finding experiment revealed more significant reductions in body weight with daily subcutaneous semaglutide at doses beyond 0.2 mg compared to daily liraglutide at 3.0 mg. The advancement of oral semaglutide for type 2 diabetes and\/or obesity is noteworthy, as alternative GLP-1 analogues are now accessible just as injectables, sometimes constraining their application. A recent experiment indicated that oral semaglutide (14 mg once day) produced superior weight reduction compared to subcutaneous liraglutide (4.4 kg vs. 3.1 kg) over a period of 26 weeks.<\/p>\n\n\n

\n
\"GLP-1<\/a>
GLP-1 monotherapy for weight loss. (Williams D M., et al<\/em>., 2020)<\/figcaption><\/figure><\/div>\n\n\n

Semaglutide molecules at BOC Sciences<\/strong><\/p>\n\n\n\n

Name<\/td>Category<\/td><\/tr>
Semaglutide Impurity 12<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 12<\/a><\/td>Impurities<\/td><\/tr>
Des-Gly(16)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Gln(17)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Glu(3)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Gly(4)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-His(1)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 1 ((Trp25-hydroxybenzyl)-Semaglutide)<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 2<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 3 (P3 Semaglutide)<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 4 (U7 Semaglutide)<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 5 (U6 Semaglutide)<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 9<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 10<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 11<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 13<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 14<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 15<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 17<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 18<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 19<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 20<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 22<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 23<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 1<\/a><\/td>Impurities<\/td><\/tr>
Des-Thr(5)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 3<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 4<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 8<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 9<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 10<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 11<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 13<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 14<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 15<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 16<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 17<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 18<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide related compound 19<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide-[Phe-d5]<\/a><\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
Semaglutide-[Phe-d8]<\/a><\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
Semaglutide-[d15]<\/a><\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
Des-[His-Aib] Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Phe(6)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-[Glu3-Gly4] Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Phe(6)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Thr(7)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Ser(8)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Val(10)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Ser(11)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Tyr(13)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-[Glu15-Gly16] Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Val(27)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Gly(29)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Arg(30)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Des-Gly(31)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Di-Ser(12)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Di-Thr(5)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Di-Thr(7)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 8<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 6<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Acetate<\/a><\/td>Inhibitor<\/td><\/tr>
Semaglutide Impurity 16<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 21<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide Impurity 7<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide sodium salt<\/a><\/td>Impurities<\/td><\/tr>
D-Ser(11)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Ser(8)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-His(1)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide-[Val-d8] Tetratrifluoroacetate<\/a><\/td>Stable Isotope Labelled Compounds<\/td><\/tr>
[D-Glu3]-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Allo-Thr(5)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Allo-Thr(7)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Asp(9)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Val(10)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Ser(12)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Tyr(13)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Leu(14)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Glu(15)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Ala(18)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Ala(19)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Lys(20)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Glu(21)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Phe(22)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Ala(24)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Trp(25)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide D-Leu26<\/a><\/td>Impurities<\/td><\/tr>
D-Val(27)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
D-Arg(28)-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
[D-Arg30]-Semaglutide<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide intermediate P29<\/a><\/td>Impurities<\/td><\/tr>
Semaglutide intermediate<\/a><\/td>Impurities<\/td><\/tr>
Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH<\/a><\/td>Impurities<\/td><\/tr>
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu<\/a><\/td>Impurities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

References<\/strong><\/strong><\/p>\n\n\n\n

    \n
  1. Idrees Z., et al<\/em>., FDA-approved pharmacotherapy for weight loss over the last decade, Cureus, 2022, 14(9).<\/li>\n\n\n\n
  2. Williams D M., et al<\/em>., Drug therapy in obesity: a review of current and emerging treatments, Diabetes Therapy, 2020, 11(6): 1199-1216.<\/li>\n\n\n\n
  3. Tak Y J., et al<\/em>., Anti-obesity drugs: long-term efficacy and safety: an updated review, The world journal of men’s health, 2021, 39(2): 208.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    History of drugs for weight loss In 1760, English physician Malcolm Flemyng was the first to refer to obesity as a disease. The public’s view of obesity could shift if […]<\/p>\n","protected":false},"author":1,"featured_media":4407,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[889],"tags":[],"_links":{"self":[{"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/posts\/4401"}],"collection":[{"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/comments?post=4401"}],"version-history":[{"count":1,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/posts\/4401\/revisions"}],"predecessor-version":[{"id":4406,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/posts\/4401\/revisions\/4406"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/media\/4407"}],"wp:attachment":[{"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/media?parent=4401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/categories?post=4401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bocsci.com\/blog\/wp-json\/wp\/v2\/tags?post=4401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}